EA201390653A1 - Aa антагонисты как усилители когнитивной и моторной функций - Google Patents
Aa антагонисты как усилители когнитивной и моторной функцийInfo
- Publication number
- EA201390653A1 EA201390653A1 EA201390653A EA201390653A EA201390653A1 EA 201390653 A1 EA201390653 A1 EA 201390653A1 EA 201390653 A EA201390653 A EA 201390653A EA 201390653 A EA201390653 A EA 201390653A EA 201390653 A1 EA201390653 A1 EA 201390653A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cognitive
- motor functions
- antagonists
- amplifiers
- adenosine
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 2
- 229960005305 adenosine Drugs 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229940098778 Dopamine receptor agonist Drugs 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 230000007659 motor function Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Описаны способы для индуцирования когнитивной и моторной функций у пациентов, страдающих болезнью Паркинсона, путем введения эффективного количества Аденозин 2а антагониста. Аденозин 2а антагонист можно опционально вводить в комбинации с предшественником допамина, таким как леводопа, или агонистом допаминовых рецепторов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/055681 WO2012060844A1 (en) | 2010-11-05 | 2010-11-05 | A2a antagonists as cognition and motor function enhancers |
PCT/US2011/059466 WO2012061787A1 (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201390653A1 true EA201390653A1 (ru) | 2013-12-30 |
EA035900B1 EA035900B1 (ru) | 2020-08-28 |
Family
ID=46024745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390653A EA035900B1 (ru) | 2010-11-05 | 2011-11-04 | Применение (4-метокси-7-морфолин-4-ил-бензотиазол-2-ил)амида 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты для лечения сонливости, связанной с болезнью паркинсона |
EA202091356A EA202091356A1 (ru) | 2010-11-05 | 2011-11-04 | A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091356A EA202091356A1 (ru) | 2010-11-05 | 2011-11-04 | A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ |
Country Status (15)
Country | Link |
---|---|
US (2) | US20130317019A1 (ru) |
EP (1) | EP2635256B1 (ru) |
JP (3) | JP6315991B2 (ru) |
KR (2) | KR102166229B1 (ru) |
CN (3) | CN109223799A (ru) |
AU (3) | AU2011323152A1 (ru) |
BR (1) | BR112013011068A2 (ru) |
CA (1) | CA2816834A1 (ru) |
EA (2) | EA035900B1 (ru) |
ES (1) | ES2842968T3 (ru) |
HK (1) | HK1245138A1 (ru) |
IL (2) | IL225868B (ru) |
MX (1) | MX2013005014A (ru) |
NZ (2) | NZ609803A (ru) |
WO (2) | WO2012060844A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6339758B2 (ja) * | 2012-07-02 | 2018-06-06 | 国立研究開発法人国立長寿医療研究センター | 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム |
JO3544B1 (ar) | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
CA3021155A1 (en) * | 2016-04-19 | 2017-10-26 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
US11246871B2 (en) | 2016-07-15 | 2022-02-15 | Northwestern University | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias |
WO2018059531A1 (zh) * | 2016-09-30 | 2018-04-05 | 苏州晶云药物科技有限公司 | 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途 |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
CA3163242A1 (en) * | 2019-12-02 | 2021-06-10 | Aarash BORDBAR | Treating cognitive disorders using trapidil |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2473864C (en) * | 2002-01-28 | 2013-06-11 | Kyowa Hakko Kogyo Co., Ltd. | Composition for use in treating patients suffering from movement disorder |
PL1753760T3 (pl) * | 2004-05-24 | 2008-06-30 | Hoffmann La Roche | (4-metoksy-7-morffolin-4-ylobenzatiazol-2-ilo)amid kwasu 4-hydroksy-4-metylopiperydyno-1-karboksylowego |
US7576073B2 (en) * | 2004-05-28 | 2009-08-18 | UNIVERSITé LAVAL | Combined therapy for the treatment of parkinson's disease |
US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
-
2010
- 2010-11-05 WO PCT/US2010/055681 patent/WO2012060844A1/en active Application Filing
-
2011
- 2011-11-04 BR BR112013011068A patent/BR112013011068A2/pt not_active IP Right Cessation
- 2011-11-04 CA CA2816834A patent/CA2816834A1/en not_active Abandoned
- 2011-11-04 EA EA201390653A patent/EA035900B1/ru not_active IP Right Cessation
- 2011-11-04 EA EA202091356A patent/EA202091356A1/ru unknown
- 2011-11-04 WO PCT/US2011/059466 patent/WO2012061787A1/en active Application Filing
- 2011-11-04 KR KR1020197005483A patent/KR102166229B1/ko active IP Right Grant
- 2011-11-04 AU AU2011323152A patent/AU2011323152A1/en not_active Abandoned
- 2011-11-04 CN CN201811049033.XA patent/CN109223799A/zh active Pending
- 2011-11-04 KR KR1020137014385A patent/KR101955045B1/ko active IP Right Grant
- 2011-11-04 CN CN2011800534450A patent/CN103429221A/zh active Pending
- 2011-11-04 NZ NZ609803A patent/NZ609803A/en not_active IP Right Cessation
- 2011-11-04 EP EP11838922.0A patent/EP2635256B1/en active Active
- 2011-11-04 CN CN201710583855.5A patent/CN107281491A/zh active Pending
- 2011-11-04 MX MX2013005014A patent/MX2013005014A/es unknown
- 2011-11-04 JP JP2013537896A patent/JP6315991B2/ja not_active Expired - Fee Related
- 2011-11-04 US US13/882,132 patent/US20130317019A1/en not_active Abandoned
- 2011-11-04 NZ NZ746118A patent/NZ746118A/en not_active IP Right Cessation
- 2011-11-04 ES ES11838922T patent/ES2842968T3/es active Active
-
2013
- 2013-04-21 IL IL225868A patent/IL225868B/en active IP Right Grant
-
2016
- 2016-08-25 JP JP2016164379A patent/JP6444951B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-02 AU AU2017201446A patent/AU2017201446A1/en not_active Abandoned
-
2018
- 2018-04-13 HK HK18104835.1A patent/HK1245138A1/zh unknown
- 2018-11-28 JP JP2018221977A patent/JP6611896B2/ja not_active Expired - Fee Related
- 2018-12-28 AU AU2018286608A patent/AU2018286608B2/en not_active Ceased
-
2019
- 2019-04-29 IL IL266321A patent/IL266321A/en unknown
-
2021
- 2021-06-07 US US17/341,106 patent/US20220125772A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
MX2010004281A (es) | Composiciones y metodos para el tratamiento de la retinopatia diabetica. | |
EA201300869A1 (ru) | Морфинановые соединения | |
ME01532B (me) | Jedinjenja | |
EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
EA201290266A1 (ru) | Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
CL2013003484A1 (es) | Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. | |
MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
CY1119560T1 (el) | Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας | |
MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
BR112013009004A2 (pt) | combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
EA201001162A1 (ru) | Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |